CMRX
Price
$8.54
Change
-$0.01 (-0.12%)
Updated
Apr 17 closing price
Capitalization
801.08M
7 days until earnings call
CRDF
Price
$2.89
Change
-$0.05 (-1.70%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
202.9M
7 days until earnings call
Ad is loading...

CMRX vs CRDF

Header iconCMRX vs CRDF Comparison
Open Charts CMRX vs CRDFBanner chart's image
Chimerix
Price$8.54
Change-$0.01 (-0.12%)
Volume$755.56K
Capitalization801.08M
Cardiff Oncology
Price$2.89
Change-$0.05 (-1.70%)
Volume$17.67K
Capitalization202.9M
CMRX vs CRDF Comparison Chart
Loading...
CMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CMRX vs. CRDF commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CMRX is a Hold and CRDF is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (CMRX: $8.54 vs. CRDF: $2.92)
Brand notoriety: CMRX and CRDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CMRX: 15% vs. CRDF: 106%
Market capitalization -- CMRX: $801.08M vs. CRDF: $202.9M
CMRX [@Biotechnology] is valued at $801.08M. CRDF’s [@Biotechnology] market capitalization is $202.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CMRX’s FA Score shows that 0 FA rating(s) are green whileCRDF’s FA Score has 0 green FA rating(s).

  • CMRX’s FA Score: 0 green, 5 red.
  • CRDF’s FA Score: 0 green, 5 red.
According to our system of comparison, CMRX is a better buy in the long-term than CRDF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CMRX’s TA Score shows that 2 TA indicator(s) are bullish while CRDF’s TA Score has 5 bullish TA indicator(s).

  • CMRX’s TA Score: 2 bullish, 1 bearish.
  • CRDF’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, CRDF is a better buy in the short-term than CMRX.

Price Growth

CMRX (@Biotechnology) experienced а -0.12% price change this week, while CRDF (@Biotechnology) price change was +4.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.07%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was -12.59%.

Reported Earning Dates

CMRX is expected to report earnings on Aug 19, 2025.

CRDF is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CMRX($801M) has a higher market cap than CRDF($203M). CMRX YTD gains are higher at: 145.402 vs. CRDF (-32.604). CRDF has higher annual earnings (EBITDA): -48.25M vs. CMRX (-92.74M). CMRX has more cash in the bank: 136M vs. CRDF (91.7M). CMRX has less debt than CRDF: CMRX (644K) vs CRDF (1.52M). CRDF has higher revenues than CMRX: CRDF (683K) vs CMRX (159K).
CMRXCRDFCMRX / CRDF
Capitalization801M203M395%
EBITDA-92.74M-48.25M192%
Gain YTD145.402-32.604-446%
P/E RatioN/AN/A-
Revenue159K683K23%
Total Cash136M91.7M148%
Total Debt644K1.52M42%
FUNDAMENTALS RATINGS
CMRX vs CRDF: Fundamental Ratings
CMRX
CRDF
OUTLOOK RATING
1..100
318
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
5089
SMR RATING
1..100
9495
PRICE GROWTH RATING
1..100
3463
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRDF's Valuation (63) in the null industry is in the same range as CMRX (92) in the Biotechnology industry. This means that CRDF’s stock grew similarly to CMRX’s over the last 12 months.

CMRX's Profit vs Risk Rating (50) in the Biotechnology industry is somewhat better than the same rating for CRDF (89) in the null industry. This means that CMRX’s stock grew somewhat faster than CRDF’s over the last 12 months.

CMRX's SMR Rating (94) in the Biotechnology industry is in the same range as CRDF (95) in the null industry. This means that CMRX’s stock grew similarly to CRDF’s over the last 12 months.

CMRX's Price Growth Rating (34) in the Biotechnology industry is in the same range as CRDF (63) in the null industry. This means that CMRX’s stock grew similarly to CRDF’s over the last 12 months.

CMRX's P/E Growth Rating (96) in the Biotechnology industry is in the same range as CRDF (100) in the null industry. This means that CMRX’s stock grew similarly to CRDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CMRXCRDF
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 8 days ago
88%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 8 days ago
75%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 8 days ago
79%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 10 days ago
88%
Declines
ODDS (%)
N/A
Bearish Trend 17 days ago
87%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 8 days ago
75%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
CMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGIKX58.14N/A
N/A
Fidelity Growth & Income K
MAPOX104.07N/A
N/A
Mairs & Power Balanced
MMCFX14.19N/A
N/A
AMG Veritas China N
PGELX24.13N/A
N/A
George Putnam Balanced R5
APFDX19.47N/A
N/A
Artisan Global Discovery Investor

CMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CMRX has been loosely correlated with QURE. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CMRX jumps, then QURE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CMRX
1D Price
Change %
CMRX100%
N/A
QURE - CMRX
52%
Loosely correlated
N/A
NAMS - CMRX
49%
Loosely correlated
+2.86%
CRDF - CMRX
44%
Loosely correlated
-4.10%
AUPH - CMRX
37%
Loosely correlated
+2.41%
FGEN - CMRX
35%
Loosely correlated
+2.70%
More

CRDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRDF has been loosely correlated with MDGL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CRDF jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDF
1D Price
Change %
CRDF100%
-4.10%
MDGL - CRDF
46%
Loosely correlated
+2.01%
CMRX - CRDF
44%
Loosely correlated
N/A
MRVI - CRDF
40%
Loosely correlated
+8.81%
ORMP - CRDF
39%
Loosely correlated
+0.66%
NAMS - CRDF
39%
Loosely correlated
+2.86%
More